Investor Overview

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

Stock Quote

Recent News

Toggle Summary Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019
MENLO PARK, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, will report
Toggle Summary Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
-  Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe -  Dermira to receive an option fee of $30 million -  Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Enters into Credit Facility with Athyrium Capital Management
Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by
Toggle Summary Dermira to Present at Evercore ISI HealthCONx Conference
MENLO PARK, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today

Upcoming Events

Copyright West LLC. Minimum 15 minutes delayed.